Adenovirus-mediated human paraoxonase1 gene transfer to provide protection against the toxicity of the organophosphorus pesticide toxicant diazoxon

Gene Therapy

Volumn 18, Issue 3, 2011, Pages 250-257

  Duysen, E G ^a   Parikh, K ^b   Aleti, V ^b   Manne, V ^b   Lockridge, O ^a   Chilukuri, N ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

adenovirus; chemical warfare nerve agents; gene delivery; organophosphorus pesticides; paraoxonase1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; ORGANOPHOSPHATE PESTICIDE; RECOMBINANT ENZYME;

ADENOVIRUS; ANIMAL EXPERIMENT; ARTICLE; CHEMICAL WARFARE; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; LD 50; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICITY; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ARYLDIALKYLPHOSPHATASE; BLOTTING, WESTERN; CELL LINE; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE TRANSFER TECHNIQUES; HUMANS; MICE; ORGANOPHOSPHORUS COMPOUNDS; PESTICIDES; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS;

ADENOVIRIDAE; MUS;

EID: 79952484251     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.136     Document Type: Article

References (41)

1. Thiermann H, Szinicz L, Eyer P, Felgenhauer N, Zilker T, Worek F. Lessons to be learnt from organophosphorus pesticide poisoning for the treatment of nerve agent poisoning. Toxicology 2007; 233: 145-154. (Pubitemid 46498387)
2. Jeyaratnam J. Acute pesticide poisoning: a major global health problem. World Health Stat Q 1990; 43: 139-144.
3. Rochu D, Chabriere E, Masson P. Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 2007; 233: 47-59. (Pubitemid 46498378)
4. Maxwell DM, Brecht KM, Chang FC, Koplovitz I, Shih TM, Sweeney RE. Toxicodynamic modeling of highly toxic organophosphorus compounds. J Mol Neurosci 2006; 30: 129-131. (Pubitemid 46035350)
5. Brimblecombe RW. Drugs acting on central cholinergic mechanisms and affecting respiration. Pharmacol Ther B 1977; 3: 65-74. (Pubitemid 8064826)
6. Gray AP. Design and structure-activity relationships of antidotes to organophosphorus anticholinesterase agents. Drug Metab Rev 1984; 15: 557-589. (Pubitemid 14011860)
7. Dirnhuber P, French MC, Green DM, Leadbeater L, Stratton JA. The protection of primates against soman poisoning by pretreatment with pyridostigmine. J Pharm Pharmacol 1979; 31: 295-299. (Pubitemid 9207593)
8. Wolfe AD, Rush RS, Doctor BP, Koplovitz I, Jones D. Acetylcholinesterase prophylaxis against organophosphate toxicity. Fundam Appl Toxicol 1987; 9: 266-270. (Pubitemid 18043755)
9. Doctor BP, Saxena A. Bioscavengers for the protection of humans against organo-phosphate toxicity. Chem Biol Interact 2005; 157-158: 167-171. (Pubitemid 41757647)
10. Raveh L, Grunwald J, Marcus D, Papier Y, Cohen E, Ashani Y. Human butyrylcholines-terase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem Pharmacol 1993; 45: 2465-2474. (Pubitemid 23189540)
11. Lenz DE, Maxwell DM, Koplovitz I, Clark CR, Capacio BR, Cerasoli DM et al. Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem Biol Interact 2005; 157-158: 205-210. (Pubitemid 41757652)
12. Cerasoli DM, Griffiths EM, Doctor BP, Saxena A, Fedorko JM, Greig NH et al. In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact 2005; 157-158: 363-365.
13. Huang YJ, Huang Y, Baldassarre H, Wang B, Lazaris A, Leduc M et al. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc Natl Acad Sci USA 2007; 104: 13603-13608. (Pubitemid 350010655)
14. Ashani Y, Pistinner S. Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model. Toxicol Sci 2004; 77: 358-367. (Pubitemid 38262609)
15. Lenz DE, Yeung D, Smith JR, Sweeney RE, Lumley LA, Cerasoli DM. Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. Toxicology 2007; 233: 31-39. (Pubitemid 46505351)
16. Stevens RC, Suzuki SM, Cole TB, Park SS, Richter RJ, Furlong CE. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc Natl Acad Sci USA 2008; 105: 12780-12784.
17. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14: 334-336.
18. Clendenning JB, Humbert R, Green ED, Wood C, Traver D, Furlong CE. Structural organization of the human PON1 gene. Genomics 1996; 35: 586-589. (Pubitemid 26270027)
19. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/ arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991; 19: 100-106.
20. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol -Vasc S 1998; 31: 329-336. (Pubitemid 28398854)
21. Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky AG et al. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol 1990; 103: 66-76. (Pubitemid 20115985)
22. Li WF, Furlong CE, Costa LG. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett 1995; 76: 219-226.
23. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A et al. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000; 10: 767-779. (Pubitemid 32042829)
24. Cowan J, Sinton CM, Varley AW, Wians FH, Haley RW, Munford RS. Gene therapy to prevent organophosphate intoxication. Toxicol Appl Pharmacol 2001; 173: 1-6. (Pubitemid 32480359)
25. Connelly S, Mech C. Delivery of adenoviral DNA to mouse liver. Methods Mol Biol 2004; 246: 37-52.
26. Clery-Barraud C, Renault F, Leva J, El Bakdouri N, Masson P, Rochu D. Exploring the structural and functional stabilities of different paraoxonase-1 formulations through electrophoretic mobilities and enzyme activity parameters under hydrostatic pressure. Biochim Biophys Acta 2009; 1794: 680-688.
27. Kuo CL, La Du BN. Comparison of purified human and rabbit serum paraoxonases. Drug Metab Dispos 1995; 23: 935-944.
28. Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P et al. Butyrylcho-linesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 2005; 70: 1673-1684. (Pubitemid 41540360)
29. Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 1545-1550. (Pubitemid 44288981)
30. Guns PJ, Van Assche T, Verreth W, Fransen P, Mackness B, Mackness M et al. Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with pre-existing atherosclerosis. Br J Pharmacol 2008; 153: 508-516. (Pubitemid 351199014)
31. Li WF, Costa LG, Furlong CE. Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health 1993; 40: 337-346. (Pubitemid 23344358)
32. Gaidukov L, Bar D, Yacobson S, Naftali E, Kaufman O, Tabakman R et al. In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes. BMC Clin Pharmacol 2009; 9: 18.
33. Fu AL, Wang YX, Sun MJ. Naked DNA prevents soman intoxication. Biochem Biophys Res Commun 2005; 328: 901-905. (Pubitemid 40238722)
34. James RW, Deakin SP. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 2004; 37: 1986-1994. (Pubitemid 39491318)
35. Moren X, Deakin S, Liu ML, Taskinen MR, James RW. HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. J Lipid Res 2008; 49: 1246-1253.
36. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590. (Pubitemid 28198486)
37. Chilukuri N, Duysen EG, Parikh K, diTargiani R, Doctor BP, Lockridge O et al. Adenovirus-transduced human butyrylcholinesterase in mouse blood functions as a bioscavenger of chemical warfare nerve agents. Mol Pharmacol 2009; 76: 612-617.
38. Chilukuri N, Duysen EG, Parikh K, Sun W, Doctor BP, Lockridge O et al. Adenovirus-mediated gene transfer of human butyrylcholinesterase results in persistent high-level transgene expression in vivo. Chem Biol Interact 2008; 175: 327-331.
39. Furlong CE, Richter RJ, Chapline C, Crabb JW. Purification of rabbit and human serum paraoxonase. Biochemistry 1991; 30: 10133-10140.
40. Kiortsis DN, Tsouli S, Lourida ES, Xydis V, Argyropoulou MI, Elisaf M et al. Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology 2005; 56: 451-458. (Pubitemid 41040531)
41. Mc DH, Ribeiro LP. Ethylene and propylene glycol in the pre-staining of lipoproteins for electrophoresis. Clin Chim Acta 1959; 4: 458-459.